| Open Trial |
Description |
| NCIC CTG EN.4 |
Who:Stages I and II high grade uterine sarcomas.
What:A phase III study to evaluate the role of adjuvant radiotherapy in the treatment of uterine sarcomas stages I and II.
Contact:Dr Paul Bessette, Dr Abdenour Nabid |
| NCIC CTG EN.5 |
Who:Stage IA grade 3, IB grade 3, IC grades 1, 2 or 3 endometrial carcinoma.
What:A phase III randomised study comparing total abdominal hysterectomy and bilateral ovariectomy (TAH BSO) versus TAH BSO plus adjuvant pelvic irradiation in the intermediate risk, stage I carcinoma of the endometrium.
Contact:Dr Paul Bessette, Dr Abdenour Nabid |
| NCIC CTG.1/GOG 0174 (to come) |
Who:Low risk gestational trophoblastic neoplasia.
What:A Randomised Phase III study of weekly parenteral Methotrexate versus "Pulsed" Dactinomycin as primary management for low risk Gestational Trophoblastic Neoplasia. (GTN)
Contact:Dr Paul Bessette |
| Altarex OVA-Gy-15 |
Who:Stage III or IV ovarian, fallopian tube or peritoneal cancer with a complete clinical response following their primary treatment (surgery and chemotherapy).
What:A Multicenter Clinical Trial Of Intravenous OvaRexT MAb-B43.13 As Post Chemotherapy Consolidation For Ovarian, Tubal And Peritoneal Carcinoma.
Contact:Dr Paul Bessette |
| NCIC CTG OV.14 |
Who:Stage IIIC or IV epithelial ovarian, fallopian tube or peritoneal cancer (biopsy proven).
What:Study comparing paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in initial tx of pts with advanced ovarian cancer.
Contact: Dr Paul Bessette, Dr Mariette Lépine. |
| NCIC CTG OV.13 |
Who:Stage IIIC or IV epithelial ovarian, fallopian tube or peritoneal cancer (biopsy proven).
What:Study comparing upfront debulking vs. neo-adjuvant chemotherapy in patients with stage IIIC or IV epithelial ovarian cancer.
Contact:Dr Paul Bessette. |
| CRM Dr Jacques Simard CHUL |
Who:Quebec families with multiple cases of breast and/or ovarian cancer.
What:Étude génétique et épidémiologique des cancers familiaux: Cancer du sein et/ou de l'ovaire. (Genetic and epidemiological study of family cancer: breast and/or ovarian cancer).
Contact:Dr Paul Bessette Dr Abdenour Nabid |
| NSABP STAR |
Who:Postmenopausal women of 35 years of age or older with an increased breast cancer risk.
What:Study of Tamoxifen and Raloxifene (STAR) for the prevention of breast cancer.
Contact:Dr Abdenour Nabid Dr Paul Bessette |
